Emerging bone problems in patients infected with human immunodeficiency virus

Clinical Infectious Diseases

Volumn 36, Issue SUPPL. 2, 2003, Pages

  Mondy, Kristin ^a   Tebas, Pablo ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RALOXIFENE; VITAMIN D;

AVASCULAR NECROSIS; BONE DISEASE; BONE METABOLISM; BONE NECROSIS; CALCIUM INTAKE; DIAGNOSTIC PROCEDURE; DIET THERAPY; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KINESIOTHERAPY; LACTIC ACIDOSIS; LUMBAR SPINE; METABOLIC DISORDER; NUTRITIONAL SUPPORT; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPINE FRACTURE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE AND BONES; BONE DISEASES, METABOLIC; HIV INFECTIONS; HUMANS; OSTEOPOROSIS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 0037386148     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/367566     Document Type: Review

References (42)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
3. Brinkman K, Hadewych JM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 1998; 12:1735-44.
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
5. Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133:192-6.
6. Chariot P, Drogou I, de L'acroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30:156-60.
7. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-70.
8. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871-5.
9. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999; 131:548.
10. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31:162-6.
11. Meyer D, Behrens G, Schmidt RE, et al. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors. AIDS 1999; 13: 1147-8.
12. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63-7.
13. Hoy J, Hudson J, Law M, et al. Osteopenia in a randomized, multicenter study of protease inhibitor (PI) substitution in patients with the lipodystrophy syndrome and well-controlled HIV viremia [abstract 208]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Washington, DC: Foundation for Retroviruses and Human Health, 2000; 114.
14. Negredo E, Gel S, Arisa ER, et al. Bone mineral density (BMD) in HIV-1-infected patients [abstract 626]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Washington, DC: Foundation for Retroviruses and Human Health, 2001; 232.
15. Manzaneque Gonzalez L, Mayoral Martin L, Jimenez Ocana C, et al. Bilateral avascular necrosis of the femur head in an HIV-positive male. Ann Med Intern 1994; 11:601-3.
16. Gibert C, Koller E, Mann M, et al. Avascular necrosis in AIDS patients receiving megestrol acetate [abstract 478]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, 1998. Washington, DC: Foundation for Retroviruses and Human Health, 2001:169
17. De Truchis P, Saillour M, Pigne E, et al. Avascular necrosis of bone in HIV-infected patients with antiphospholipid antibodies [abstract Mo.B.1298]. Int Conf AIDS 1996; 11:106.
18. Stovall D Jr, Young TR. Avascular necrosis of the medial femoral condyle in HIV-infected patients. Am J Orthop 1995;24:71-3.
19. Gerster JC, Camus JP, Chave JP, et al. Multiple site avascular necrosis in HIV infected patients. J Rheumatol 1991; 18:300-2.
20. Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137:17-25.
21. NIH Consensus Development Panel on Osteoporosis, Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-95.
22. Nevitt MC, Johnell O, Black DM, et al. Bone mineral density predicts non-spine fractures in very elderly women. Study of Osteoporotic Fractures Research Group. Osteoporos Int 1994;4:325-31.
23. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72-5.
24. Ross PD, Davis JW, Epstein RS, et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114:919-23.
25. Paton NIJ, Macallan DC, Griffin GE, et al. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 1997;61:30-2.
26. Lawal A, Engelson E, Wang J, Heymsfield SB, Kotler DP. Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS 2001; 15:278-80.
27. McGowan I, Cheng A, Coleman S, et al. Assessment of bone mineral density (BMD) in HIV-ingected antiretroviral-therapy-naive patients [abstract 628]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). 2001.
28. Knobel H, Guelar A, Valecillo G, Nogues X, Diez A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment?.AIDS 2001; 15:807-8.
29. Hernandez Quero J, Ortego Centeno N, Munoz-Torres M, et al. Alterations in bone turnover in HIV-positive patients. Infection 1993; 21:220-2.
30. McNurlan MA, Garlick PJ, Frost RA, et al. Albumin synthesis and bone collagen formation in human immunodeficiency virus-positive subjects: differential effects of growth hormone administration. J Clin Endocrinol Metab 1998; 83:3050-5.
31. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999; 84:145-50.
32. Serrano S, Marinoso ML, Soriano JC, et al. Bone remodelling in human immunodeficiency virus-1-infected patients: a histomorphometric study. Bone 1995; 16:185-91.
33. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482-90.
34. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001; 15:1823-9.
35. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001; 15:703-9.
36. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31:257-75.
37. Baran DT, Faulkner KG, Genant HK, et al. Diagnosis and management of osteoporosis: guidelines for the utilization of bone densitometry. Calcified Tissue International 1997; 61:433-40.
38. Miller PD, Zapalowski C, Kulak CA, et al. Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab 1999; 84:1867-71.
39. Monier P, McKown K, Bronze MS. Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31:1488-92.
40. Brown P, Crane L. Avascular necrosis of bone in patients with human immunodeficiency virus infection: report of 6 cases and review of the literature. Clin Infect Dis 2001; 32:1221-6.
41. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivatio to 1,25-dihydroxyvitamin D. AIDS 2003; 17:513-520.
42. Wang MWH, Teitelbaum SL, Tebas P, et al. Indinavir inhibits bone formation while ritonavir inhibits osteoclast differentiation and function [abstract 541]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Washington, DC: Foundation for Retroviruses and Human Health, 2001:206.